on Andera Partners
Andera Partners and Bpifrance Lead €27 Million Series B for EG 427
In a strategic move, Andera Partners and Bpifrance have co-led a €27 million Series B funding round for EG 427. This injection of capital aims to finance the ongoing phase 1b/2a clinical study of EG110A and further develop the company's proprietary HERMES vector technology platform. Specialist fund SCI Ventures and existing investors also participated in this round.
The funding supports the evaluation of EG110A, which targets neurogenic detrusor overactivity in spinal cord injury patients. The initiative aims to address critical neuro-urology pathologies. This financing facilitates EG 427's broader genetic medicine pipeline, with potential advancements in neuro-urology treatments.
The development employs non-replicative HSV vectors, promising affordable production costs and potential repeated dosing advantages. This approach could revolutionize treatments for neurological diseases, positioning EG 427 at the forefront of genetic medicine innovations.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Andera Partners news